These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23359796)

  • 1. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy.
    Jin Y; Qiu MZ; Wang DS; Zhang DS; Ren C; Bai L; Luo HY; Wang ZQ; Wang FH; Li YH; Xu RH
    PLoS One; 2013; 8(1):e53149. PubMed ID: 23359796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
    Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 4. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
    Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
    Liang Y; Zhao L; Chen H; Lin T; Chen T; Zhao M; Hu Y; Yu J; Liu H; Li G
    BMC Cancer; 2021 Feb; 21(1):196. PubMed ID: 33632161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer.
    Karagkounis G; Squires MH; Melis M; Poultsides GA; Worhunsky D; Jin LX; Fields RC; Spolverato G; Pawlik TM; Votanopoulos KI; Levine EA; Schmidt C; Bloomston M; Cho CS; Weber S; Masi A; Berman R; Pachter HL; Staley CA; Newman E; Maithel SK; Hatzaras I
    J Gastrointest Surg; 2017 Dec; 21(12):1984-1992. PubMed ID: 28963709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
    Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
    Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
    Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
    Cho JH; Lim JY; Cho JY
    PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis.
    Wu L; Feng Y; Wu Z; Xu H; Zhang C; Ning J; Wang R; Chen J; Xie M; Zhang Y; Bu L; Hao J; Ma T
    World J Surg Oncol; 2021 Sep; 19(1):272. PubMed ID: 34507562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
    Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
    Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors related to patient propensity to receive adjuvant chemotherapy and outcomes in stage III gastric cancer cases after D2 surgery.
    Chen JS; Hung CY; Liu KH; Tsai CY; Kuo YC; Hsu JT; Chou WC
    Asian J Surg; 2019 May; 42(5):604-612. PubMed ID: 30249414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic influence of D2 lymphadenectomy with para-aortic lymph nodal dissection for gastric cancer in N3 stage].
    Liang YX; Liang H; Ding XW; Wang XN; Zhang L; Wu LL; Liu HG; Jiao XG
    Zhonghua Wai Ke Za Zhi; 2013 Dec; 51(12):1071-6. PubMed ID: 24499714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
    Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
    Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
    Norero E; Bustos M; Herrera ME; Cerda J; González P; Ceroni M; Martínez C; Briceño E; Rojas H; Cártes R; Lopez V; Hidalgo V; Báez S; Caracci M; Viñuela E; Díaz A
    Eur J Surg Oncol; 2016 Jan; 42(1):94-102. PubMed ID: 26577767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study.
    Shi JW; Zhou Y; Wu S
    Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10472-10480. PubMed ID: 37975371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
    Lu W; Zeng X; Li N; Liu H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.